Skip to Content

Clinical Trials Detail

GOG 0213 Phase III randomized controled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum sensitive recurent ovarian peritoneal primary and fallopian TUV cancer

Objective
Clinical trial of Carboplatin and Paclitaxel administered by IV, which is considered standard of care and Bevacizumab administered by IV and is investigational.
IRB Protocol Number
07-1235
Principal Investigator(s)
SUSAN DAVIDSON

Cancer Trials

  • Female Reproductive Cancer
Sponsor(s)
GOG
Contact
REBECCA KISSANE at 720-848-7202
or REBECCA.KISSANE@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to nine months. A follow up period that will continue for the rest of your life. // Eligibility criteria include but are not limited to 18 years or older with ovarian, fallopian tube or peritoneal primary cancer.